Dow Gains 50 Points; US Crude Oil Inventories Rise
Portfolio Pulse from Lisa Levin
US stocks traded higher with the Dow Jones gaining around 50 points. US crude oil inventories climbed by 3.954 million barrels, against market estimates of a 1.912 million decline. HireRight Holdings Corporation (HRT) plans an additional $25 million share repurchase program. Rocket Pharmaceuticals (RCKT) reached alignment with the FDA on a global Phase 2 pivotal trial. DZS Inc. (DZSI) secured $29.7 million in financing. Eiger BioPharmaceuticals (EIGR) discontinued a Phase 3 study, Calidi Biotherapeutics (CLDI) shares fell following its public debut, and KULR Technology Group (KULR) reported pricing of a public offering of common stock.
September 13, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DZS Inc. secured $29.7 million in financing.
Securing financing can provide a company with the necessary capital to invest in growth opportunities, which could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
HireRight plans an additional $25 million share repurchase program.
Share repurchase programs are generally seen as a positive signal by the market, indicating that the company believes its shares are undervalued. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Rocket Pharmaceuticals reached alignment with the FDA on a global Phase 2 pivotal trial.
Positive regulatory news, such as alignment with the FDA on a trial, is typically seen as a positive signal by the market and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Calidi Biotherapeutics shares fell following its public debut.
Shares falling following a public debut is typically seen as a negative signal by the market, indicating a lack of investor confidence. This could lead to a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Eiger BioPharmaceuticals discontinued a Phase 3 study.
Discontinuing a Phase 3 study is typically seen as a negative signal by the market, indicating potential issues with the drug under development. This could lead to a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
KULR Technology Group reported pricing of a public offering of common stock.
The pricing of a public offering can dilute existing shares, which could lead to a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100